Bethesda-based health technology company RightEye LLC has acquired exclusive rights to tests it says could help doctors diagnose autism and Parkinson’s disease earlier and more accurately than ever before.
Baltimore Innovation Week is in full swing, with a schedule of more than 65 events ranging from student hack-a-thons to panel discussions about gender equality in technology.
Now in its fifth year, Baltimore Innovation Week is intended to celebrate Baltimore’s startup and technology community and offer a way in for people who want to get involved.
Next Proposal Deadline October 14, 2016
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-based StableFastTM Biomanufacturing Platform, a proprietary system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The companies are actively working together to further optimize productivity. Momenta has the right to obtain an exclusive research and commercial license to StableFastTM for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.
We are pleased to announce that Greenfield/Belser has won the BioHealth Capital Region logo competition. Several members of their creative team contributed to the winning design:
The winning icon is a modern and vibrant rendition of a double helix that also gives a nod to the geography of the BioHealth Capital region, with the diamond shape of DC in the center. The blue and green colors connote health and vitality. The blue right-pointing arrowhead echoes the tagline: Advancing Science/Accelerating Innovation.
We received over 80 submissions from design firms, colleges, and freelance designers from Maryland, Virginia and DC. Each entry was carefully evaluated by a panel of 14 reviewers who considered both practical and aesthetic factors. The panel selected Greenfield/Belser as the winning designer and worked with the firm on several iterations of the icon and wordmark to arrive at the final design.
Next Proposal Deadline October 14, 2016
Market-driven new technology and innovation leads to new products and new jobs. Creating jobs in innovative Maryland companies is what the Maryland Industrial Partnerships (MIPS) program has been doing for 27 years: bringing the inventive minds and extensive laboratory resources of the University System of Maryland (USM) to bear on creating the new products that feed the growth of Maryland businesses. Since the program’s inception in 1987, MIPS–enabled products have generated sales of $30.3 B. MIPS is nationally recognized by the U.S. Small Business Administration as a model program for best practices in transferring technology and is a proven program that contributes significantly to job creation and high tech product development in Maryland.
For Martine Rothblatt, nothing is off limits. Not even death.
The founder of Sirius XM Satellite Radio and United Therapeutics Corp. (NASDAQ: UTHR) is the quintessential innovator who lives life asking the question: “Why can’t we?”
Things aren’t what they used to be at the Virginia Economic Development Partnership. The state agency will lose its international trade division next spring, along with 17 percent of its staff and about a quarter of its budget.
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-based StableFastTM Biomanufacturing Platform, a proprietary system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The companies are actively working together to further optimize productivity. Momenta has the right to obtain an exclusive research and commercial license to StableFastTM for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.
NEA Partner Sara Nayeem, MD will serve on the Best Legal Frameworks for VC Investments Panel on Thursday, September 22 in DC at the International Bar Association Meeting.
The International Bar Association programme will feature more than 200 substantive legal sessions, workshops and panels, including topics on current events and contentious issues facing the profession. The committee sessions will offer the chance to hear from the best experts in the field. The conference will also feature sessions presenting the lessons and achievements of each of my Presidential Task Forces: on Climate Change Justice and Human Rights, the Judicial Integrity Initiative, Human Trafficking, and Independence of the Legal Profession.
Wednesday, October 26, 2016
For over 10 years the Sartorius Stedim Upstream & Downstream Forum has provided an exciting venue for presentations, networking and discussions focusing on the latest applications and technologies.
This year the event continues to build the collaborative bridge between Upstream/Downstream Bioprocessing by bringing specialists from your peer group who will share their experience by presenting best practices, applications and techniques to address the bottlenecks at the interfaces of upstream and downstream. Seize the opportunity of this unique venue and book both events as a package.